In the management of patients with RAS wild-type metastatic colorectal cancer (mCRC), anti-epidermal growth factor receptor (EGFR) therapies have demonstrated a clinical benefit, with longer survival. | Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment A study protocol